

This year at CPhI Worldwide (November 9-11, 2021; Fiero Milano), Datwyler (Booth 6F10) will showcase its StarterPack™, a complete, ready-to-use packaging system that can help create an uninterrupted transition from the drug development stage to commercial launch.
With the global supply chain crisis causing drug shortages for critical, life-threatening diseases, more than ever, it is crucial for drug manufacturers to ensure that they can efficiently bring new therapies to market. Coupled with the fact that the market for parenteral drugs has also been steadily growing over the last decade, addressing patient needs and protecting the integrity of the parenteral drugs while minimizing time to market has become paramount.
Supporting the development of parenteral drugs, the StarterPack™ contains high-performance components offering an ideal sealing compatibility to prevent leaks and other seal integrity concerns throughout manufacturing and handling, helping to minimize challenges along the path to production.
Even before the pandemic, the challenges posed by the nature of developing a new medicine proved to be difficult and has significantly hindered time to market. Drug manufacturers have always aimed to minimize time to market while also protecting injectables against contamination. Our StarterPack™ can help move the industry forward in achieving this goal.
Massimo Mainetti
Global Head of Marketing and Product Management
Developed to provide drug developers with a range of compatible primary and secondary packaging components to be used in every drug development application, the StarterPack™ enables manufacturers to incorporate high-quality components and commercial packaging solutions into their testing and clinical trial strategy including diagnostic research, clinical trials, and product launches. Helping to minimize time during early stages, quantities can also be ramped up once drug products are ready for commercial launch.
The StarterPack™ contains the company’s OmniFlex® stoppers alongside adaptiQ® vials from SCHOTT. The OmniFlex® stoppers are 100 percent spray coated with a proprietary, inert, no-added silicone, fluoropolymer, providing a robust barrier between drug and rubber to minimize extractables and leachables. Datwyler’s StarterPack™ also contains Datwyler’s PrimeCaps™ which are made with the highest quality alloy optimized with an Accurim straight skirt edge and present low bioburden and particulate levels. The combination of the Datwyler OmniFlex® stopper, PrimeCap™, and SCHOTT adaptiQ® glass vial, offers a comprehensive packaging solution to ensure drug efficacy, stability, and, ultimately, patient safety.
Datwyler manufactures its OmniFlex® stoppers to FirstLine® production standards. At CPhI Worldwide, representatives will be available to discuss how the company’s network of FirstLine® facilities marry best-in-class production technologies with fully integrated cleanroom environments in plant locations across the world to maximize geographical options for sourcing.